News
Patient knowledge and understanding of radiation from diagnostic imaging is lacking, according to a research letter published online Dec. 31, 2012, in JAMA Internal Medicine . More than half of patients surveyed heard nothing in the media about radiation from medical imaging, and many of those aware of radiation exposure substantially underestimated dose.
Read more at healthimaging.com
We at PRRTinfo.org are working with the Society of Nuclear Medicine and Molecular Imaging to provide information for patients on the benifits and risks of nuclear diagnostic and treatment. To learn more about molecular imaging please see discovermi.org.
For the second year in a row, NorCal CarciNET Community and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a patient education day during the SNMMI's Annual Meeting. The program took place on June 8th and began with three (3) general lectures about the definition of nuclear medicine and molecular imaging, safety of nuclear medicine, the value of patient and physician partnerships in care management. The afternoon concluded with breakout sessions focused on hot topics in
A method of molecular imaging that pinpoints hormonally active tissues in the body could change the course of treatment for a remarkable number of neuroendocrine cancer patients, say researchers at the Society of Nuclear Medicine's 59th Annual Meeting.
Results of the study indicated that PET/CT and Ga-68 DOTATATE was highly sensitive and specific for assessing neuroendocrine tumors and changed thecourse of treatment for a large number of patients. Prior to imaging, more than half of the
Photos from Warmth Manila
Click here to view on non flash device.
Click on the photo to see full screen and to download.
Ga-68-labeled somatostatin analogs are important imaging agents to detect and manage neuroendocrine tumors (NETs). The SNMMI formed the 68Ga Users Group to advance the use of these imaging agents in the US. Members of the Users Group developed harmonized release criteria, an imaging manual, generic data collection forms and a draft informed consent form to aid the community in establishing investigator-sponsored trials. In October 2013, the Society of Nuclear Medicine and Molecular Imaging
On April 10, 2012 a 42 center worldwide trial of PRRT using LU177 was announced with sites in the US and Europe.
Detailed Description:
A multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study. In this study, treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care (30 mg Octreotide LAR) will be compared to treatment with high dose (60 mg) Octreotide LAR in patients with inoperable, somatostatin receptor positive, histologically proven